The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Top Cited Papers
- 15 February 2005
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 105 (4) , 1383-1395
- https://doi.org/10.1182/blood-2004-07-2909
Abstract
Besides its role as an essential regulator of physiologic and pathologic angiogenesis, vascular endothelial growth factor (VEGF) triggers growth, survival, and migration of leukemia and multiple myeloma cells; plays a pivotal role in hematopoiesis; inhibits maturation of dendritic cells; and increases osteoclastic bone-resorbing activity as well as osteoclast chemotaxis. Dysregulation of VEGF expression and signaling pathways therefore plays an important role in the pathogenesis and clinical features of hematologic malignancies, in particular multiple myeloma. Direct and indirect targeting of VEGF and its receptors therefore may provide a potent novel therapeutic approach to overcome resistance to therapies and thereby improve patient outcome.Keywords
This publication has 248 references indexed in Scilit:
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Metronomic scheduling: the future of chemotherapy?The Lancet Oncology, 2001
- The Hallmarks of CancerCell, 2000
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996
- Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endotheliumNature, 1995
- Failure of blood-island formation and vasculogenesis in Flk-1-deficient miceNature, 1995
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993